Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy

Figure 2 Probability of hepatic encephalopathy recurrence during rifaximin therapy in the subgroup “Prevention of recurrent hepatic encephalopathy”, n = 29; Kaplan-Meier method. ¹Censored data correspond to discontinuation of treatment before the occurrence of hepatic encephalopathy (HE). At the end of follow-up, it corresponded to “HE-free” patients, after six months of treatment.